Cardiovascular disease Archives

Home Cardiovascular disease

Latest Posts

Shutterstock 657615100 heart surgery repair

Podcast 10 Nov 2023

How biotech can mend a broken heart

CellProthera has been working to do the impossible – mend broken hearts. The biotech company’s ProtheraCytes cell therapy regenerates damaged tissue following a heart attack, thus restoring cardiac function. In…

November 10, 2023 - 5 minutesmins - By Jim Cornall

In Depth 19 May 2023

Can cardiovascular diseases be cured? The future of heart treatment

Cardiovascular diseases, characterized as a group of disorders of the heart and blood vessels, are the leading cause of death worldwide. In fact, in the U.S. alone, it is thought…

May 19, 2023 - 11 minutesmins - By Willow Shah-Neville

Anastasiia Slynko biotech investment 744x368 1

In Depth 11 Oct 2022

The biggest private biotech investments in September 2022

The companies Acelyrin, InnovaFeed and Arsenal Biosciences bagged the biggest biotech investments in September 2022, with insect protein and cell therapies attracting big funding rounds. Autumn is in full swing…

October 11, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 17 Jul 2023

Lilly boosts obesity portfolio with Versanis Bio acquisition

Eli Lilly and Company is set to acquire Versanis Bio in a deal that could be worth close to $2 billion. Versanis Bio is a private clinical-stage biopharmaceutical company focused…

July 17, 2023 - 2 minutesmins - By Jim Cornall

Best in Biotech 8 Jun 2023

Six companies that have made their name in the cardiovascular space

Cardiovascular disease is a general term used to describe a disease that affects the heart and blood vessels. According to the World Health Organization (WHO), cardiovascular diseases are the leading…

June 8, 2023 - 7 minutesmins - By Willow Shah-Neville

News and Trends 26 Apr 2023

LincRNA discovery could lead to targeted treatments

Our genetic code includes more than 15,000 specific sections that can be made into molecules called lincRNAs. Some of these sections can occur in coiled-up sections of our genome called…

April 26, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 11 Apr 2023

Calida Therapeutics launches to tackle thrombo-inflammatory disorders

Calida Therapeutics, a preclinical stage biotech company specializing in thrombo-inflammatory disorders, has announced its incorporation in Paris, France. Calida Therapeutics has already raised €2 million ($2.17 million) in seed funding…

April 11, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 31 Mar 2023

Destiny Pharma gel reduces nasal staph in surgery patients

Destiny Pharma has revealed data showing its drug reduced Staphylococcus aureus in the nasal passage of pre-op cardiac surgery patients. Destiny Pharma is a clinical stage biotechnology company focused on…

March 31, 2023 - 3 minutesmins - By Jim Cornall

Novartis Cardiovascular Canakinumab Phase III

News and Trends 22 Jun 2017

Novartis Scores Major Phase III Win with New Cardiovascular Drug

Novartis just announced that its anti-inflammatory drug, canakinumab, was able to clear a 10,000-plus patient Phase III trial for cardiovascular disease. Novartis most recently boasted impressive Phase III results for its AMD drug, RTH258, that…

June 22, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 30 Sep 2015

Gecko’s Heart surgery glue the new Cover of Science’s Translational Medicine

Gecko Biomedical is a young Parisian biotech which is now featured on the front cover of the Science Journal for Translational Medicine. We explore their surgery adhesive tech inspired by…

September 30, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 3 Sep 2014

EMA give Orphan Drug Designation to the CER-001 of Cerenis

Cerenis Therapeutics, the biopharmaceutical company developing CER-001, an engineered human apoA-I-containing pre-beta HDL mimetic, for the treatment of cardiovascular disease, announced today that it has received two separate Orphan Drug…

September 3, 2014 - 3 minutesmins - By Joachim Eeckhout

News and Trends 20 Mar 2017

French Biotech fails Second Phase II Trial for Cardiovascular Disease

Cerenis therapeutic's lead candidate CER-001 has failed Phase II for the treatment of patients with post-acute coronary syndrome (ACS). The French-based Biotech Cerenis is developing therapies for the treatment of cardiovascular…

March 20, 2017 - 3 minutesmins - By Melanie De Almeida

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

Download Inpart’s latest report

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inpart, the leading platform for biopharma partnering